Nearly 30 percent patients with breast cancer gained weight after receiving chemotherapy treatment, suggested a study.

The study was published in the journal BMC Medicine. Beyond weight gain, chemotherapy is also known to increase the risk of high blood pressure and glucose intolerance, a prediabetes condition. Although this is a familiar phenomenon, the mechanisms underlying these processes have not yet been identified.

Dr Ayelet Shai initiated the research study. He is Director of Oncology at the Galilee Medical Center, who led the study with Professor Omry Koren, an expert in gastrointestinal bacteria at the Azrieli Faculty of Medicine of Bar-Ilan University. Dr Shai said that symptoms she has witnessed as an oncologist led her to initiate the study: "In my clinical work with women recovering from breast and gynaecological tumours, I have seen many of them gain weight following treatment and experience difficulty returning to their original weight. When I read in the medical literature about the link between the microbiome and obesity in people without cancer, I thought it would be interesting to see if the microbiome of patients is one of the causes of obesity and other metabolic changes," she said.

The study conducted by Dr Shai and Prof Koren involved 33 women who were about to begin chemotherapy for breast cancer and gynaecological cancer. The women were weighed once before the treatment, and once again approximately five weeks after treatment began. Prior to treatment, a stool sample was used to genetically characterize the microbiome of each of the women. Nine of the women were found to have gained weight to a degree that was defined as significant (3 percent or more). The microbiome of these women exhibited a smaller diversity of gut bacteria and different bacterial strains compared to that of the women who did not experience weight gain.

The study showed that the composition of intestinal bacteria may predict which women will gain weight as a result of chemotherapy. In addition, when the gut microbiota of women who gained weight were transferred to germ-free mice, they developed glucose intolerance and signs of the chronic inflammatory condition were detected in their blood. These findings suggest that bacteria are partially responsible for metabolic changes that lead to weight gain following chemotherapy treatment. "We have shown for the first time that the pre-treatment microbiome of patients that gained weight following chemotherapy is different than the microbiome of patients that did not gain weight and that faecal transplantation from patients that gained weight results in glucose intolerance, adverse lipid changes and inflammatory changes in germ-free mice," said Prof Koren. These results suggest that the intestinal microbiome is mediating metabolic changes in women treated by chemotherapy. Moreover, the pre-chemotherapy composition of the intestinal microbiome can predict which patients will gain weight following treatment.

Dr Shai and Prof Koren are currently in the midst of a follow-up study which aims to examine the results in a larger patient population and to examine the microbiome of women at the end of chemotherapy in order to understand the effect of the treatment on bacterial composition. The researchers also plan to study the effect of chemotherapy on obesity in germ-free mice following faecal transplantation. If the results obtained in the initial study are repeated, it will be possible to consider a stool test for women before starting treatment, so that the patient knows if she is at risk of gaining weight. As October marks Breast Cancer Awareness Month, Dr Shai said, "We hope that in the future we will be able to identify those women who are at risk for weight gain through a simple examination and perhaps even suggest ways to prevent this phenomenon."